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Gender disparities in diabetes and coronary heart
disease medication among patients with type 2
diabetes: results from the DIANA study
Heike U Krämer1†, Elke Raum1*†, Gernot Rüter2, Ben Schöttker1, Dietrich Rothenbacher3, Thomas Rosemann4,
Joachim Szecsenyi5 and Hermann Brenner1
Abstract
Background: Coronary heart disease (CHD) is one of the most common long-term complications in people with
type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among
people with type 2 diabetes.
Methods: The study was based on data from the baseline examination of the DIANA study, a prospective cohort
study of 1,146 patients with type 2 diabetes conducted in South-West Germany. Information on diabetes and CHD
medication was obtained from the physician questionnaires. Bivariate and multivariate analyses using logistic
regression were employed in order to assess associations between gender and prescribed drug classes.
Results: In total, 624 men and 522 women with type 2 diabetes with a mean age of 67.2 and 69.7 years,
respectively, were included in this analysis. Compared to women, men had more angiopathic risk factors, including
smoking, alcohol consumption and worse glycemic control, and had more often a diagnosed CHD. Bivariate
analyses showed higher prescription of thiazolidinediones and oral combination drugs as well as of
angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers and aspirin in men than in women. After
full adjustment, differences between men and women remained significant only for ACE inhibitors (OR = 1.44; 95%-
confidence interval (CI): 1.11 – 1.88) and calcium channel blockers (OR = 1.42, 95%-CI: 1.05 – 1.91).
Conclusions: These findings contribute to current discussions on gender differences in diabetes care. Men with
diabetes are significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers
in the presence of coronary heart disease, respectively. Our results suggest, that diabetic men might be more
thoroughly treated compared to women. Further research is needed to focus on reasons for these differences
mainly in treatment of cardiovascular diseases to improve quality of care.
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Background
Type 2 diabetes mellitus (T2DM) is a major public
health concern. It induces macro- and microvascular
damage promoting long-term complications, like coron-
ary heart disease (CHD), stroke or diabetic nephropathy,
and is associated with significant morbidity and mortal-
ity [1,2]. The risk of CHD and stroke is altered by age,
gender, insulin and glycemic control in patients with dia-
betes mellitus [3], but gender-specific differences in the
prevalence of cardiovascular diseases (CVD) might also
decrease with rising age, especially in older women with
diabetes compared to men of the same age [4].
Diabetes and CVD treatment is complex: besides the
different applicable agents, disease status, comorbidities,
self-management capabilities and individual compliance of
patients have to be considered by the treating physicians
[5,6]. Diabetes treatment is generally intensified if CVD
risk factors or comorbidities, such as hypertension, hyper-
cholesterolemia or CHD, are present and vice versa [7,8].
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However, there is evidence that women tend to receive
a less adequate therapeutic management than men
[9,10]. Until now, it is still unclear to what extent these
gender differences can be explained by confounding fac-
tors, such as age, diabetes duration, adherence, prevalent
depression or marital status [1,11].
We aimed to analyze whether or not gender disparities
exist in diabetes and CHD medication after controlling
for the most important confounding factors in an out-
patient population of diabetic patients in Germany.
Methods
Study design and study population
This analysis is based on data from the baseline examin-
ation of the DIANA study (Type 2 Diabetes Mellitus:
New Approaches to Optimize Medical Care in General
Practice). DIANA is an epidemiological prospective co-
hort study with patients with T2DM conducted in the
Ludwigsburg-Heilbronn area located in South-West
Germany. The study was initiated in 2008 to address
(short- and long-term) diabetes-related outcomes and to
evaluate potentials for health care improvements in
people with T2DM. People with a physician diagnosed
T2DM aged 18 and older were recruited consecutively
according to a standardized protocol by 38 general practi-
tioners (GP) during regular practice visits between October
2008 and March 2010. The study protocol was approved
by the Ethics Committees of the medical faculty of the
University of Heidelberg and of the Chamber of Physicians
of Baden-Württemberg.
Data collection
Participating patients completed a self-administered
standardized questionnaire at baseline. Information
related to diabetes and other medical conditions was
reported by the attending physician through a standar-
dized questionnaire. GPs reported all diabetes-relevant
physician-diagnosed comorbidities (‘yes’/ ‘no’) and sub-
mitted a complete list of all medications currently pre-
scribed. Diabetes medication and CHD medication were
classified according to the Anatomic Therapeutic Chem-
ical (ATC) classification system (for more detailed infor-
mation on classification see Additional file 1).
A blood sample was collected by the GP at time of re-
cruitment and glycated haemoglobin A1c (HbA1c) was
assessed by a central laboratory, using ion exchange high
pressure liquid chromatography (HPLC) (G8, Tosoh
Biosciences).
Definition of key variables
For the following variables information from the GP
questionnaire was used and they were defined accord-
ingly: body mass index (BMI) in kg/m², most recent high
density lipoprotein level (HDL) in mg/dl and blood
pressure (systolic/ diastolic) in mmHg, duration of dia-
betes and participation in a disease management pro-
gram for T2DM (DMP-DM). CHD was defined as
prevalent CHD or past myocardial infarction. Antidia-
betic drugs were differentiated in biguanide, sulfony-
lurea, alpha-glucosidase inhibitor, thiazolidinedione,
glinide, glucagon-like peptide-I (GLP-I) analogue exena-
tide, dipeptidyl peptidase-4 (DPP-4) inhibitor, oral com-
bination drug (counted as one drug) and insulin
treatment in general. Insulins were further specified in
short acting human insulin, intermediate acting insulin
(basal insulin), (human) insulin combination (short and
intermediate acting) and insulin analogue. CHD medica-
tion was differentiated in antihypertensive drug, i.e.
angiotensin-converting enzyme (ACE) inhibitor, diuretic,
beta-blocker, calcium channel blocker and other hyperten-
sive drug, such as angiotensin II receptor blocker, lipid
lowering medication and aspirin (see Additional file 1).
The following information was obtained form the par-
ticipant questionnaires: age at time of recruitment, gen-
der, level of school education, marital status,
occupational status, smoking history and alcohol con-
sumption as well as number of appointments with the
GP. Information on participants’ self-estimated adherence
to all prescribed medications was obtained by the 4-item
self-report Morisky medication adherence questionnaire
developed [12]. The sum score was calculated ranging
from 0 (full adherence) to 4 (poor adherence). Patients
were grouped as having a good (zero points), moderate (1
to 2 points) or poor adherence (3 to 4 points). The general
health status was evaluated by the first question of the
short-form-12 (SF-12) questionnaire [13].
Classification of glycemic control level was based on
baseline HbA1c, defining ≤ 6.4% as good, 6.5% - 7.4% as
moderate and ≥7.5% as poor [14].
Statistical analysis
When information from the GPs’ was not available (only
3.8% of the participants), information from the partici-
pants’ questionnaires was used to minimize missing
values, since we found very good agreement of both
sources for participants for whom the information of
both questionnaires was available (kappa coefficients for
medications: >0.90 and for comorbidities: >0.80).
Descriptive statistics included 2-tailed t-tests for means
and χ²-tests for proportions comparing differences be-
tween men and women. Analyzed covariates were socio-
demographic characteristics, glycemic control, smoking
status, alcohol consumption, diabetes duration, participa-
tion in a DMP-DM and comorbidities. Analyses on pre-
scribed diabetes medication were stratified for gender and
differentiated between the presence and absence CHD.
Analyses on prescribed CHD medication were stratified
for gender and restricted to participants with prevalent
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CHD. Logistic regression was employed to estimate un-
adjusted and adjusted odds ratios (ORs) and correspond-
ing 95% confidence intervals (95%-CIs) for describing the
association between gender and use of diabetes or CHD
medication. In order to adjust for the main independent
determinants, variables for multivariate logistic regression
models were selected by backward selection separately for
each medication group (diabetes and CHD medications).
Variables with a p-value < 0.1 were kept in the model to
limit potential confounding. Statistical testing was two-
sided, an alpha level of 5% was applied, and SAS 9.2 (SAS
Institute, Cary, N.C., USA) was used throughout.
Results
Overall, 624 men (54.4%) and 522 women (45.6%) parti-
cipated in this study (Table 1). On average, men were
younger than women. Gender-specific differences also
were found for other socio-demographic factors: women
had a lower educational level, were more often singles
and less often still employed. Smoking and alcohol con-
sumption was far more prevalent in men than in
women. Tentatively, more men than women showed a
HbA1c ≥ 7.5%. Men had significantly lower mean HDL
levels than women. No gender differences were found
for mean systolic or diastolic blood pressure. The num-
ber of GP appointments did not differ significantly be-
tween women and men. Self-reported medication
adherence and self-rated general health status were simi-
lar between women and men. Men had significantly
more often physician-diagnosed CVD and diabetes-
related comorbidities, including CHD, intermittent clau-
dication, stroke and diabetic nephropathy, whereas
women had significantly more often a diagnosed
depression.
Characteristics of diabetes medication stratified for
gender and prevalent coronary heart disease are
described in Table 2. Significantly more men than
women took at least one diabetes medication (men:
77.7% vs. women: 69.6%, p = 0.01). The most frequently
prescribed diabetes drugs in men and women were
biguanides, sulfonylureas and insulins. The prescription
of more expensive diabetes drugs, such as GLP-I analo-
gues, DPP-4 inhibitors and oral combination drugs, was
rather low among our study participants. Statistically sig-
nificant gender-specific differences were evident for thia-
zolidinediones (p = 0.04) and oral combination drugs
(p = 0.02). Overall, prescription of insulin (insulin or in-
sulin analogue) was almost equally frequent among men
and women, but was far more common among patients
with CHD than without. The number of diabetes
medications was statistically significantly increasing
with level of glycemic control in men and women
(Figures 1 and 2).
Table 1 Description of the study population
Men Women p-value
(n = 624) (n = 522)
Variables of interest n % n %
Age in years (mean, SD*) 67.2 (10.1) 69.7 (10.5)
Age in years
≤59 137 22.0 84 16.1
60 - 69 193 30.9 129 24.7
70 - 79 239 38.3 231 44.3
≥80 55 8.8 78 14.9 0.0001
Years of school education
≤9 433 70.9 395 76.9
10 - 12 104 17.0 94 18.2
≥13 74 12.1 25 4.9 0.0001
Marital status
Single/ widowed/ divorced 112 18.1 209 40.2
Married 508 81.9 311 59.8 <0.0001
Occupational status
Employed 158 26.5 78 15.7
Retired 403 67.5 318 63.9
Housewife 0 0 80 16.1
Other 36 6.0 22 4.4 <0.0001
Smoking history
Never 174 28.0 375 72.0
Ex-smoker 355 57.2 100 19.2
Current smoker 92 14.8 46 8.8 <0.0001
Alcohol consumption
Abstainer 139 22.3 283 54.2 <0.0001
Body mass index (kg/m²)
<25 76 12.2 78 14.9
25 - <30 255 40.9 187 35.8
30 - <35 194 31.1 161 30.8
≥35 98 15.8 96 18.4 0.19
Glycemic control by HbA1c
Good (≤6.4%) 241 38.6 213 41.1
Moderate (6.5 - 7.4%) 239 38.3 212 40.9
Poor (≥7.5%) 144 23.1 93 18.0 0.10
Mean HbA1c (SD) in % 6.9 (1.1) 6.8 (1.0) 0.14
Mean HDL (SD) in mg/dl 47.7 (14.3) 57.3 (17.2) <0.0001
Mean systolic BP (SD) in mmHg 137.8
(18.1)
136.8
(19.0)
0.41
Mean diastolic BP (SD) in mmHg 79.4 (10.2) 79.6 (10.5) 0.68
Physician reported time since diabetes diagnosis
≤5 years 241 38.6 213 40.8
6 – 10 years 185 29.7 146 28.0
11 – 15 years 104 16.7 81 15.5
≥16 years 94 15.1 82 15.7 0.82
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Table 3 shows the prevalence of CHD medication
stratified by gender. Statistically significant gender-
specific differences were found for ACE inhibitors
(p = 0.003), calcium channel blockers (p = 0.01) and as-
pirin (p = 0.002). In the group of CHD patients, statisti-
cally significant gender-specific differences were only
evident for ACE inhibitors (p = 0.02) and calcium chan-
nel blockers (p = 0.004).
The results of logistic regression analyses regarding
the association between gender and diabetes and CHD
medications with significant gender differences (p < 0.05)
are described in Table 4. Men had 53% increased odds
to receive any antidiabetic drug compared to women
(95%-CI: 1.17 – 1.99, no table). Men compared to
women had 1.8 and 2.5 higher odds to receive thiazolidi-
nediones and oral combination drugs. After stratification
for CHD, no significant gender-specific difference in dia-
betes medication was seen. After full model adjustment
men had still 44% and 42% increased odds to receive
ACE inhibitors and calcium channel blockers. A positive
association between male gender and antithrombotic
therapy with aspirin was also observed. In participants
with CHD, gender-specific prescription differences of
ACE inhibitors and calcium channel blockers were par-
ticularly strong. Significant gender differences in ACE
inhibitors in CHD patients with diabetes sustained after
adjusting for age, Hba1c, appointements with GP, medi-
cation adherence and comorbidities that are indications
for renin-angiotensin system (RAS) blockade. Overall, all
logistic regression models showed a very good model fit
by Hosmer-Lemeshow test.
Discussion
Our results demonstrate that men with diabetes were
significantly more likely to receive oral combination
drugs, ACE inhibitors and calcium channel blockers for
CHD than women. Gender-specific differences could
also be observed for aspirin use for the overall study
sample, but not for the CHD subsample. Taken together,
these patterns suggest that diabetic men might be more
thoroughly treated than women, especially in terms of
CHD medication. Furthermore, the number of diabetes
medication was significantly increasing with the level of
glycemic control and diabetes duration in men and
women with diabetes.
Our finding of gender-specific, also not statistically
significant differences in the prescription of diabetes
medication such as thiazolidinediones is in accordance
with the results of a German cross-sectional study [15]:
Lehnert et al. analyzed data on 6,786 people with dia-
betes in primary care and found a slightly higher pre-
scription rate of thiazolidinediones in men (4.4%) than
in women (3.6%) above the age of 60 years. Apart from
the different time frames of the studies (Lehnert et al.:
2001; our study: 2008–2010), differences in prescription
rates might be mainly explained by disparities in diabetes
duration (Lehnert et al.: 4.5 (±1.2 years) vs. our study: 8.8
(±7.1 years)) which is one of the main determinants of
treatment choice. Reasons for the higher prescription of
thiazolidinediones in men than in women are unclear.
Studies have suggested that thiazolidinediones have bene-
ficial effects on inflammatory and atherogenic parameters,
blood pressure and microalbuminuria [16] and that thia-
zolidinediones doubles the risk of fractures among
women, but not among men with diabetes [17]. Due to se-
vere side effects the most frequently prescribed thiazolidi-
nediones, namely Rosiglitazone and Pioglitazone, can no
Table 1 Description of the study population (Continued)
Appointments with GPs
(last 3 months)
≤1 260 41.7 197 37.9
2 – 3 245 39.3 216 41.5
≥4 119 19.1 107 20.6 0.43
Participation in a DMP-DM 471 79.4 398 81.7 0.34
Medication adherence
Good 455 75.6 385 77.0
Moderate 132 21.9 102 20.4
Poor 15 2.5 13 2.6 0.83
General health status (self-rated)
Excellent or very good 62 10.0 40 7.7
Good 366 58.7 291 55.8
Fair 174 27.9 172 32.9
Poor 21 3.4 19 3.6 0.21
Physician diagnosed comorbidities
Hypertension 488 78.3 407 78.1 0.93
Hypercholesterolemia 350 56.2 300 57.8 0.58
Coronary heart disease 147 23.6 67 12.8 <0.0001
Heart failure 75 12.0 64 12.3 0.89
Intermittent claudication 96 15.4 36 6.9 <0.0001
Stroke 47 7.5 22 4.2 0.02
Nephropathy 76 12.2 45 8.6 0.05
Retinopathy 51 8.2 35 6.7 0.35
Neuropathy 144 23.1 104 20.0 0.20
Depression 67 10.7 97 18.6 0.0002
Cancer 63 10.1 49 9.4 0.70
*SD = standard deviation; HbA1c = glycated haemoglobin A1c; GP = general
practitioner;
DMP-DM=disease management program for treatment of patients with type
2 diabetes.
Missing values: education: 21, marital status: 6, occupational status: 51,
smoking: 4, BMI: 1, HbA1c: 4, HDL: 270, systolic and diastolic BP: 70,
appointments with GPs: 2, DMP-DM: 66, adherence: 44, health status: 1,
hypertension: 2, hypercholesterolemia: 4, CHD: 2, heart failure: 1, intermittent
claudication: 1, stroke: 2, nephropathy: 1, retinopathy: 1, depression: 1, cancer: 1
Significant results (p < 0.05) by χ² test are printed bold.
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longer be prescribed for diabetes treatment in Germany
since April 2011 [18], and Rosiglitazone was recom-
mended for suspension by the European Medicines
Agency (EMA) in September 2010 [19].
The higher prescription rate of oral combination drugs
in men compared to women with T2DM might be
explained by the higher number of comorbidities and
burden of disease in participating men compared to
Table 2 Diabetes medication by gender and prevalent coronary heart disease
Medication of interest With coronary heart
disease
Without coronary heart
disease
Men Women Men Women Men Women
(n = 624) (n = 522) (n =147) (n = 67) (n = 477) (n = 455)
n % n % n % n % n % n %
Number of diabetes medication (mean, STD*) 1.3 (1.1) 1.3 (1.2) 1.5 (1.3) 1.4 (1.1) 1.3 (1.1) 1.2 (1.2)
Number of diabetes medication
0 138 22.3 158 30.4 27 18.5 15 22.7 111 23.5 143 31.6
1 245 39.6 175 33.7 50 34.3 22 33.3 195 41.2 153 33.8
2 159 25.7 113 21.8 46 31.5 17 25.8 113 23.9 96 21.2
3 and more 77 12.4 73 14.1 23 15.7 12 18.2 54 11.4 61 13.5
Biguanide 343 55.0 273 52.3 70 47.6 35 52.2 273 57.2 238 52.3
Sulfonylurea 132 21.2 92 17.6 32 21.8 14 20.9 100 21.0 78 17.1
Alpha-glucosidase inhibitor 14 2.2 13 2.5 5 3.4 1 1.5 9 1.9 12 2.6
Thiazolidinedione 39 6.3 19 3.6 11 7.5 3 4.5 28 5.9 16 3.5
Glinide 21 3.4 13 2.5 6 4.1 1 1.5 15 3.1 12 2.6
Glucagon-like peptide-I analogue (GLP-I) exenatide 6 1.0 5 1.0 4 2.7 0 0 2 0.4 5 1.1
Dipeptidyl peptidase-4 (DPP-4) inhibitor 20 3.2 28 5.4 7 3.3 4 6.0 17 3.6 24 5.3
Oral combination drug 26 4.2 9 1.7 6 4.1 1 1.5 20 4.2 8 1.8
Insulin treatment 123 19.8 107 20.5 43 29.7 20 29.8 80 16.8 87 19.1
Short acting insulin 47 7.5 40 7.7 16 10.9 7 10.4 31 6.5 33 7.3
Intermediate acting (basal insulin) 53 8.5 56 10.7 19 12.9 10 14.9 34 7.1 46 10.1
Human insulin combination (short and intermediate acting) 22 3.5 14 2.7 8 5.4 4 6.0 14 2.9 10 2.2
Insulin analogue 58 9.3 43 8.2 22 15.0 8 11.9 36 7.5 35 7.7
*SD = standard deviation. Number may not always add up to total because of missing values for some items.
Significant results (p < 0.05) by χ²-test are printed bold.
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Figure 1 Mean number (± standard error) of diabetes medication by glycemic control.
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women and the attempt of the general practitioners to
reduce the overall number of medication especially for
men.
Our findings regarding CHD medication are in line
with previous research: The results of the Euro Heart
Survey on Heart Failure including 8,914 patients with
heart failure showed that women got less ACE inhibitors
and beta-blockers than men [20]. A German cross-
sectional study on 1,857 consecutive patients with heart
failure likewise showed a difference in the prescription
of ACE inhibitors and dosage of beta-blockers, and
revealed a less evidence-based treatment in women than
in men [21]. For patients with diabetes mellitus, a Swed-
ish study including 229 primary care centres revealed -
similar to our study - that men were more often pre-
scribed ACE inhibitors than women and that only one
third of the patients below 75 years was on lipid-
lowering drug therapy [22]. The higher prescription rate
of ACE inhibitors among men can potentially be
explained not only by the higher CVD comorbidity, but
also by the higher prevalence of nephropathy in men
than in women and the protective effect of ACE inhibi-
tors towards progression of nephropathy [23]. Brann-
ström et al [24] investigated gender disparities in the
pharmacological treatment of cardiovascular disease and
diabetes mellitus in a cohort of elderly people aged
85 years or older. Women received significantly more
drugs, more diuretics, more nitrates. In contrast to our
study, no differences were found for insulin therapy, As-
pirin and ACE inhibitors, but ACE inhibitor prescription
rates were considerably lower in this study compared to
ours. For patients with coronary events or revascularisa-
tion the EUROASPIRE III study found higher ACE-
inhibitors prescription rates for men than for women.
Women receive more diuretics, insulin and oral antidia-
betic agents [25]. Lipid lowering treatment is generally
recommended for all people with T2DM with a high risk
for macroangiopathic complications or with CHD [26].
The underuse of lipid lowering drugs together with a
lack of antithrombotic drugs might point to a
Figure 2 Mean number (± standard error) of diabetes medication by diabetes duration.
Table 3 Coronary heart disease medication by gender and prevalent coronary heart disease
Medication of interest All With coronary heart disease
Men Women Men Women
(n= 624) (n = 522) (n =147) (n = 67)
n % n % n % n %
Antihypertensive drug 507 81.3 412 78.9 144 98.0 63 94.0
Angiotensin-converting enzyme (ACE) inhibitor 431 69.1 316 60.5 120 81.6 45 67.2
Diuretic 186 29.9 176 33.7 70 47.9 34 50.7
Beta-blocker 267 42.8 228 43.7 112 76.2 48 71.6
Calcium channel blocker 168 26.9 106 20.3 50 34.0 10 14.9
Lipid lowering drug 277 44.4 216 41.4 110 74.8 45 67.2
Aspirin 213 34.1 133 25.5 102 69.4 45 67.2
Number may not always add up to total because of missing values for some items. Significant results (p < 0.05) by Χ² test are printed bold.
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suboptimal quality of health care, because both are cru-
cial for the reduction of cardiovascular comorbidity and
all-cause mortality in people with diabetes [27-29]. A
large Danish primary care study [30] on patients
screened for diabetes with a high risk for CVD and a
large US retrospective study [31] on people with diabetes
found that less women than men received an adequate
lipid-lowering treatment. In our study which was con-
ducted between 2008 and 2010, already 43% of the
patients with diabetes received lipid lowering drugs, but
with no differences between men and women.
In summary, as various studies [32,33] and a recently
published review [34] point out, gender differences
regarding diabetes mellitus are present for all steps in
the glucometabolic pathway starting with differences in
patho-physiological disturbances, the risk factor distribu-
tion, incidence and prevalence of complications, and
finally diagnostic techniques and therapy. Franconi
et al conclude, that a gender specific approach for
all aspects of patient care is much needed to im-
prove overall perspective of patients with diabetes
mellitus [34].
Our study results are limited by the cross-sectional
study design, i.e. causality cannot be derived and no con-
clusion on trends in treatment can be drawn. In particu-
lar, our study did not allow identifying with certainty the
potential reasons underlying gender differences in medi-
cation. The relatively small numbers in each medication
group limited the power to detect differences of small
and moderate size. Although we aimed for the inclusion
of all people with T2DM in a large number of practices,
selection effects of participating GPs and regional vari-
ation in treatment might limit generalizability. Further-
more, the insurance status was not recorded at baseline.
We could not perform a detailed monitoring of com-
pleteness of recruitment of diabetes patients in the
practices.
Conclusions
Men with diabetes were significantly more likely to re-
ceive oral combination drugs, ACE inhibitors and cal-
cium channel blockers in the presence of coronary heart
disease. These patterns suggest that diabetic men might
be more thoroughly treated than women, especially in
Table 4 Results of diabetes and coronary heart disease medication: Odds ratios (95% confidence intervals) for men
compared to women (reference)
Total With coronary heart disease Without coronary heart disease
Diabetes Medication
Thiazolidinedione Crude 1.77 (1.01 - 3.09) 1.73 (0.47 - 1.58) 1.71 (0.91 - 3.21)
Adjusteda 1.75 (0.99 - 3.08) 1.58 (0.41 - 6.07) 1.68 (0.89 - 3.17)
Adjustedb 1.42 (0.79 - 2.57)1 0.94 (0.28 - 3.17)2 1.52 (0.81 - 2.85)3
Oral combination drug Crude 2.48 (1.51 - 5.34) 2.81 (0.33 - 23.79) 2.45 (1.07 - 5.61)
Adjusteda 1.97 (0.94 - 4.13) 1.82 (0.21 - 15.96) 1.91 (0.82 - 4.45)
Adjustedb 2.06 (0.98 - 4.31)4 1.93 (0.38 - 9.78)5 1.87 (0.84 - 4.13)6
Coronary Heart Disease Medication
Angiotensin-converting enzyme inhibitor Crude 1.46 (1.14 – 1.86) 2.17 (1.12 – 4.20)
Adjusteda 1.52 (1.18 – 1.95) 2.18 (1.09 – 4.35)
Adjustedc 1.44 (1.11 – 1.88)7 -
Adjustedd - 2.61 (1.26 – 5.42)8
Calcium channel blocker Crude 1.45 (1.10 – 1.91) 2.94 (1.38 – 6.24)
Adjusteda 1.55 (1.17 – 2.06) 3.53 (1.58 – 7.89)
Adjustedc 1.42 (1.05 – 1.91)9 -
Adjustedd 3.64 (1.55 – 8.52)10
Aspirin Crude 1.52 (1.17 – 1.96) 1.10 (0.58 – 2.08)
Adjusteda 1.80 (1.38 – 2.36) 0.96 (0.49 – 1.87)
Adjustede 1.36 (1.01 – 1.84)11 -
Adjustedf - 1.12 (0.57 – 2.21)12
Adjusted for: aage and HbA1c level,
bage, HbA1c level, physician reported diabetes duration, appointments with the GP, marital status, diabetic nephropathy,
depression, cage, HbA1c level, appointments with the GP, medication adherence, coronary heart disease, stroke, intermittent claudication, diabetic nephropathy
and depression, dage, HbA1c level, appointments with the GP, medication adherence, stroke, intermittent claudication, diabetic nephropathy and depression,
eage,
HbA1c level, appointments with the GP, medication adherence, coronary heart disease, stroke, diabetic nephropathy and depression,
fage, HbA1c level,
appointments with the GP, medication adherence, stroke, diabetic nephropathy and depression.
Goodness of fit: 1p = 0.74; 2p = 0.87; 3p = 0.33; 4p = 0.66; 5p = 0.85 6p = 0.66; 7p = 0.83; 8p = 0.46; 9p = 0.93; 10p = 0.70; 11p = 0.13; 12p = 0.76.
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terms of CHD medication. We hope that our results will
contribute to and stimulate the discussion on gender-
specific disparities in diabetes healthcare.
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